CareDx (CDNA) Tops Q3 EPS by 41c, provides guidance

CareDx (NASDAQ: CDNA) reported Q3 EPS of ($0.18), $0.41 better than the analyst estimate of ($0.59). Revenue for the quarter came in at $67.2 million versus the consensus estimate of $53.14 million.

Guidance:

For the full year 2023, CareDx expects revenue to be in the range of $274 to $278 million, versus the consensus of $255.4 million.

For earnings history and earnings-related data on CareDx (CDNA) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• UBS Reiterates Buy Rating on General Motors (GM) as Defense Opportunity in Focus
• Creatd files Form S-1 and reports Q1 2026 financial results